EcoDrugPlus

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSORLG00000018018
Gene Symbol: FYNB
4 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSORLG00000015447
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSORLG00000002368
Gene Symbol: HCK
4 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSORLG00000007773
Gene Symbol: ITK
4 Cross references
205 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1a

Ensembl ID : ENSORLG00000009703
Gene Symbol: IMPDH1A
3 Cross references
258 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSORLG00000015224
Gene Symbol: IMPDH1B
4 Cross references
257 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSORLG00000002914
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSORLG00000010063
Gene Symbol: JAK1
4 Cross references
212 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSORLG00000010002
Gene Symbol: JAK2A
4 Cross references
199 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSORLG00000001504
Gene Symbol: JAK2B
3 Cross references
194 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSORLG00000004401
Gene Symbol: KITB
4 Cross references
200 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSORLG00000024102
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).